Cardio Diagnostics
CDIO
15 hedge funds and large institutions have $374K invested in Cardio Diagnostics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.05% less ownership
Funds ownership: 0.27% → 0.22% (-0.05%)
6% less funds holding
Funds holding: 16 → 15 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
62% less capital invested
Capital invested by funds: $996K → $374K (-$622K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$4.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.04K |
| 3 |
Morgan Stanley
New York
|
+$405 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$50K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$31.6K |
| 3 |
Jones Financial Companies
Des Peres,
Missouri
|
-$3.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$368 |
CDIO Hedge Fund Activity: Q3 2024 in Review
15 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Cardio Diagnostics (CDIO) for Q3 2024, worth a combined $374K — down 62% from $996K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CDIO and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $4.5K. The largest seller was UBS Group, exiting entirely with an estimated $50K sold.
- 15 institutional investors held Cardio Diagnostics (CDIO) as of Q3 2024, down from 16 in Q2 2024.
- Funds reported $374K of Cardio Diagnostics stock for Q3 2024, down 62% quarter-over-quarter.
- 2 funds opened new Cardio Diagnostics positions in Q3 2024 and 3 closed out, a net change of -1 holder.
- The largest Cardio Diagnostics buyer in Q3 2024 was HRT Financial, an estimated $4.5K added.
- The largest Cardio Diagnostics seller in Q3 2024 was UBS Group, an estimated $50K sold.
Based on aggregated 13F filings for Q3 2024.